U.S. Markets close in 2 hrs 36 mins

Achilles Therapeutics plc (ACHL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.84+0.03 (+0.53%)
As of 1:15PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close5.81
Open5.78
Bid6.10 x 800
Ask6.23 x 1200
Day's Range5.78 - 5.89
52 Week Range5.45 - 18.95
Volume37,592
Avg. Volume129,467
Market Cap240.38M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.83
  • GlobeNewswire

    Achilles Therapeutics to Present at Upcoming Investor Conferences

    LONDON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that management will present at the following investor conferences in September. Wells Fargo Virtual Healthcare Conference on Friday, September 10, 2021 at 10:40am ET / 3:40pm UKH.C. Wainwright 23rd Annual Global Investment Conference available beginning Monday, September 13, 2021 at 7:00am ET

  • GlobeNewswire

    Achilles Therapeutics Announces Grant of US and European Patents

    LONDON, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that US patent US 11,098,121 and European patent EP3347039B have been granted. The patents cover a method of identifying cancer patients that are likely to respond to a checkpoint inhibitor (CPI) by determining the total number of clonal neoantigens or the ratio of clonal to subclonal neoantigen

  • GlobeNewswire

    Achilles Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Highlights

    – Presentations of translational science data at AACR and ASCO illustrate crucial path to potency assay – – Data from ten patients across CHIRON and THETIS studies anticipated in the fourth quarter of 2021 – LONDON, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced its financial results for the second quarter ended June 30, 2021, and recent business hi